1tr7 › Citations

Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.

Bouckaert J, Berglund J, Schembri M, De Genst E, Cools L, Wuhrer M, Hung CS, Pinkner J, Slättegård R, Zavialov A, Choudhury D, Langermann S, Hultgren SJ, Wyns L, Klemm P, Oscarson S, Knight SD, De Greve H
Mol Microbiol 55 441-55 (2005)
Cited: 211 times
EuropePMC logo PMID: 15659162

Abstract

Mannose-binding type 1 pili are important virulence factors for the establishment of Escherichia coli urinary tract infections (UTIs). These infections are initiated by adhesion of uropathogenic E. coli to uroplakin receptors in the uroepithelium via the FimH adhesin located at the tips of type 1 pili. Blocking of bacterial adhesion is able to prevent infection. Here, we provide for the first time binding data of the molecular events underlying type 1 fimbrial adherence, by crystallographic analyses of the FimH receptor binding domains from a uropathogenic and a K-12 strain, and affinity measurements with mannose, common mono- and disaccharides, and a series of alkyl and aryl mannosides. Our results illustrate that the lectin domain of the FimH adhesin is a stable and functional entity and that an exogenous butyl alpha-D-mannoside, bound in the crystal structures, exhibits a significantly better affinity for FimH (Kd = 0.15 microM) than mannose (Kd = 2.3 microM). Exploration of the binding affinities of alpha- d-mannosides with longer alkyl tails revealed affinities up to 5 nM. Aryl mannosides and fructose can also bind with high affinities to the FimH lectin domain, with a 100-fold improvement and 15-fold reduction in affinity, respectively, compared with mannose. Taken together, these relative FimH affinities correlate exceptionally well with the relative concentrations of the same glycans needed for the inhibition of adherence of type 1 piliated E. coli. We foresee that our findings will spark new ideas and initiatives for the development of UTI vaccines and anti-adhesive drugs to prevent anticipated and recurrent UTIs.

Articles - 1tr7 mentioned but not cited (8)

  1. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex. Wellens A, Garofalo C, Nguyen H, Van Gerven N, Slättegård R, Hernalsteens JP, Wyns L, Oscarson S, De Greve H, Hultgren S, Bouckaert J. PLoS One 3 e2040 (2008)
  2. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. Askew EB, Gampe RT, Stanley TB, Faggart JL, Wilson EM. J Biol Chem 282 25801-25816 (2007)
  3. The affinity of the FimH fimbrial adhesin is receptor-driven and quasi-independent of Escherichia coli pathotypes. Bouckaert J, Mackenzie J, de Paz JL, Chipwaza B, Choudhury D, Zavialov A, Mannerstedt K, Anderson J, Piérard D, Wyns L, Seeberger PH, Oscarson S, De Greve H, Knight SD. Mol Microbiol 61 1556-1568 (2006)
  4. Effect of Adiantum philippense Extract on Biofilm Formation, Adhesion With Its Antibacterial Activities Against Foodborne Pathogens, and Characterization of Bioactive Metabolites: An in vitro-in silico Approach. Adnan M, Patel M, Deshpande S, Alreshidi M, Siddiqui AJ, Reddy MN, Emira N, De Feo V. Front Microbiol 11 823 (2020)
  5. Sites for Dynamic Protein-Carbohydrate Interactions of O- and C-Linked Mannosides on the E. coli FimH Adhesin. Touaibia M, Krammer EM, Shiao TC, Yamakawa N, Wang Q, Glinschert A, Papadopoulos A, Mousavifar L, Maes E, Oscarson S, Vergoten G, Lensink MF, Roy R, Bouckaert J. Molecules 22 E1101 (2017)
  6. Dimeric and Trimeric Fusion Proteins Generated with Fimbrial Adhesins of Uropathogenic Escherichia coli. Luna-Pineda VM, Reyes-Grajeda JP, Cruz-Córdova A, Saldaña-Ahuactzi Z, Ochoa SA, Maldonado-Bernal C, Cázares-Domínguez V, Moreno-Fierros L, Arellano-Galindo J, Hernández-Castro R, Xicohtencatl-Cortes J. Front Cell Infect Microbiol 6 135 (2016)
  7. GC/MS Analyses of the Essential Oils Obtained from Different Jatropha Species, Their Discrimination Using Chemometric Analysis and Assessment of Their Antibacterial and Anti-Biofilm Activities. Gamal El-Din MI, Youssef FS, Altyar AE, Ashour ML. Plants (Basel) 11 1268 (2022)
  8. Why a diaminopyrrolic tripodal receptor binds mannosides in acetonitrile but not in water? Vila-Viçosa D, Francesconi O, Machuqueiro M. Beilstein J Org Chem 10 1513-1523 (2014)


Reviews citing this publication (71)

  1. The biology and future prospects of antivirulence therapies. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. Nat Rev Microbiol 6 17-27 (2008)
  2. Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era. Kostakioti M, Hadjifrangiskou M, Hultgren SJ. Cold Spring Harb Perspect Med 3 a010306 (2013)
  3. From carbohydrate leads to glycomimetic drugs. Ernst B, Magnani JL. Nat Rev Drug Discov 8 661-677 (2009)
  4. Host-pathogen interactions in urinary tract infection. Nielubowicz GR, Mobley HL. Nat Rev Urol 7 430-441 (2010)
  5. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ. FEMS Microbiol Rev 36 616-648 (2012)
  6. Structural biology of the chaperone-usher pathway of pilus biogenesis. Waksman G, Hultgren SJ. Nat Rev Microbiol 7 765-774 (2009)
  7. A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics. Ghazarian H, Idoni B, Oppenheimer SB. Acta Histochem 113 236-247 (2011)
  8. Design and creativity in synthesis of multivalent neoglycoconjugates. Chabre YM, Roy R. Adv Carbohydr Chem Biochem 63 165-393 (2010)
  9. Extraintestinal pathogenic Escherichia coli. Smith JL, Fratamico PM, Gunther NW. Foodborne Pathog Dis 4 134-163 (2007)
  10. Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Sivick KE, Mobley HL. Infect Immun 78 568-585 (2010)
  11. Catch-bond mechanism of force-enhanced adhesion: counterintuitive, elusive, but ... widespread? Sokurenko EV, Vogel V, Thomas WE. Cell Host Microbe 4 314-323 (2008)
  12. Antibiofilm polysaccharides. Rendueles O, Kaplan JB, Ghigo JM. Environ Microbiol 15 334-346 (2013)
  13. Enhancing oral vaccine potency by targeting intestinal M cells. Azizi A, Kumar A, Diaz-Mitoma F, Mestecky J. PLoS Pathog 6 e1001147 (2010)
  14. Targeting virulence not viability in the search for future antibacterials. Heras B, Scanlon MJ, Martin JL. Br J Clin Pharmacol 79 208-215 (2015)
  15. Intervention with bacterial adhesion by multivalent carbohydrates. Pieters RJ. Med Res Rev 27 796-816 (2007)
  16. Immunoglobulin domains in Escherichia coli and other enterobacteria: from pathogenesis to applications in antibody technologies. Bodelón G, Palomino C, Fernández LÁ. FEMS Microbiol Rev 37 204-250 (2013)
  17. Prevention of bacterial adhesion. Klemm P, Vejborg RM, Hancock V. Appl Microbiol Biotechnol 88 451-459 (2010)
  18. Recent advances in intravesical drug/gene delivery. Tyagi P, Wu PC, Chancellor M, Yoshimura N, Huang L. Mol Pharm 3 369-379 (2006)
  19. Adhesive organelles of Gram-negative pathogens assembled with the classical chaperone/usher machinery: structure and function from a clinical standpoint. Zav'yalov V, Zavialov A, Zav'yalova G, Korpela T. FEMS Microbiol Rev 34 317-378 (2010)
  20. Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections. O'Brien VP, Hannan TJ, Nielsen HV, Hultgren SJ. Microbiol Spectr 4 (2016)
  21. Survey of the year 2005 commercial optical biosensor literature. Rich RL, Myszka DG. J Mol Recognit 19 478-534 (2006)
  22. FimH and Anti-Adhesive Therapeutics: A Disarming Strategy Against Uropathogens. Sarshar M, Behzadi P, Ambrosi C, Zagaglia C, Palamara AT, Scribano D. Antibiotics (Basel) 9 E397 (2020)
  23. Anti-adhesion methods as novel therapeutics for bacterial infections. Cozens D, Read RC. Expert Rev Anti Infect Ther 10 1457-1468 (2012)
  24. Stopping bacterial adhesion: a novel approach to treating infections. Bavington C, Page C. Respiration 72 335-344 (2005)
  25. The sweet connection: Solving the riddle of multiple sugar-binding fimbrial adhesins in Escherichia coli: Multiple E. coli fimbriae form a versatile arsenal of sugar-binding lectins potentially involved in surface-colonisation and tissue tropism. Korea CG, Ghigo JM, Beloin C. Bioessays 33 300-311 (2011)
  26. Targeting Biofilms Therapy: Current Research Strategies and Development Hurdles. Jiang Y, Geng M, Bai L. Microorganisms 8 E1222 (2020)
  27. From physiology to pharmacy: developments in the pathogenesis and treatment of recurrent urinary tract infections. Silverman JA, Schreiber HL, Hooton TM, Hultgren SJ. Curr Urol Rep 14 448-456 (2013)
  28. Pathoblockers or antivirulence drugs as a new option for the treatment of bacterial infections. Calvert MB, Jumde VR, Titz A. Beilstein J Org Chem 14 2607-2617 (2018)
  29. Adhesive Pili in UTI Pathogenesis and Drug Development. Spaulding CN, Hultgren SJ. Pathogens 5 E30 (2016)
  30. Molecular force spectroscopy on cells. Liu B, Chen W, Zhu C. Annu Rev Phys Chem 66 427-451 (2015)
  31. A review on anti-adhesion therapies of bacterial diseases. Asadi A, Razavi S, Talebi M, Gholami M. Infection 47 13-23 (2019)
  32. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease. Mydock-McGrane LK, Hannan TJ, Janetka JW. Expert Opin Drug Discov 12 711-731 (2017)
  33. Recurrent urinary tract infections in women. Aydin A, Ahmed K, Zaman I, Khan MS, Dasgupta P. Int Urogynecol J 26 795-804 (2015)
  34. The giant adhesin SiiE of Salmonella enterica. Barlag B, Hensel M. Molecules 20 1134-1150 (2015)
  35. Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease. Mydock-McGrane LK, Cusumano ZT, Janetka JW. Expert Opin Ther Pat 26 175-197 (2016)
  36. Glycans in drug discovery. Valverde P, Ardá A, Reichardt NC, Jiménez-Barbero J, Gimeno A. Medchemcomm 10 1678-1691 (2019)
  37. Strategies for the Development of Glycomimetic Drug Candidates. Hevey R. Pharmaceuticals (Basel) 12 E55 (2019)
  38. Invited review: Anti-adhesive properties of bovine oligosaccharides and bovine milk fat globule membrane-associated glycoconjugates against bacterial food enteropathogens. Douëllou T, Montel MC, Thevenot Sergentet D. J Dairy Sci 100 3348-3359 (2017)
  39. The potential of FimH as a novel therapeutic target for the treatment of Crohn's disease. Sivignon A, Bouckaert J, Bernard J, Gouin SG, Barnich N. Expert Opin Ther Targets 21 837-847 (2017)
  40. Glycosylation of uroplakins. Implications for bladder physiopathology. Kątnik-Prastowska I, Lis J, Matejuk A. Glycoconj J 31 623-636 (2014)
  41. Targeting virulence traits: potential strategies to combat extraintestinal pathogenic E. coli infections. Dobrindt U, Hacker J. Curr Opin Microbiol 11 409-413 (2008)
  42. Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs. Ogawara H. J Antibiot (Tokyo) 74 24-41 (2021)
  43. Urinary tract infections in multiple sclerosis. Phé V, Pakzad M, Curtis C, Porter B, Haslam C, Chataway J, Panicker JN. Mult Scler 22 855-861 (2016)
  44. Bacterial surface appendages as targets for novel antibacterial therapeutics. Steadman D, Lo A, Waksman G, Remaut H. Future Microbiol 9 887-900 (2014)
  45. Chemical attenuation of pilus function and assembly in Gram-negative bacteria. Lo AW, Moonens K, Remaut H. Curr Opin Microbiol 16 85-92 (2013)
  46. Glycan-mediated molecular interactions in bacterial pathogenesis. Lee S, Inzerillo S, Lee GY, Bosire EM, Mahato SK, Song J. Trends Microbiol 30 254-267 (2022)
  47. Lectin functionalized nanocarriers for gene delivery. Gajbhiye V, Gong S. Biotechnol Adv 31 552-562 (2013)
  48. Novel Strategies to Combat Bacterial Biofilms. Hemmati F, Rezaee MA, Ebrahimzadeh S, Yousefi L, Nouri R, Kafil HS, Gholizadeh P. Mol Biotechnol 63 569-586 (2021)
  49. Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives. De Nunzio C, Bartoletti R, Tubaro A, Simonato A, Ficarra V. Antibiotics (Basel) 10 373 (2021)
  50. Bioisosteres of Carbohydrate Functional Groups in Glycomimetic Design. Hevey R. Biomimetics (Basel) 4 E53 (2019)
  51. Considerations on D-mannose Mechanism of Action and Consequent Classification of Marketed Healthcare Products. Scaglione F, Musazzi UM, Minghetti P. Front Pharmacol 12 636377 (2021)
  52. Developments in Mannose-Based Treatments for Uropathogenic Escherichia coli-Induced Urinary Tract Infections. Hatton NE, Baumann CG, Fascione MA. Chembiochem 22 613-629 (2021)
  53. What contributes to an effective mannose recognition domain? Sager CP, Eriş D, Smieško M, Hevey R, Ernst B. Beilstein J Org Chem 13 2584-2595 (2017)
  54. Therapies in early development for the treatment of urinary tract inflammation. Zacchè MM, Giarenis I. Expert Opin Investig Drugs 25 531-540 (2016)
  55. Systematic review of the effect of D-mannose with or without other drugs in the treatment of symptoms of urinary tract infections/cystitis (Review). Parazzini F, Ricci E, Fedele F, Chiaffarino F, Esposito G, Cipriani S. Biomed Rep 17 69 (2022)
  56. Targeting Dynamical Binding Processes in the Design of Non-Antibiotic Anti-Adhesives by Molecular Simulation-The Example of FimH. Krammer EM, de Ruyck J, Roos G, Bouckaert J, Lensink MF. Molecules 23 E1641 (2018)
  57. The glycobiology of uropathogenic E. coli infection: the sweet and bitter role of sugars in urinary tract immunity. Lupo F, Ingersoll MA, Pineda MA. Immunology 164 3-14 (2021)
  58. A Natural Alternative Treatment for Urinary Tract Infections: Itxasol©, the Importance of the Formulation. Cela-López JM, Camacho Roldán CJ, Gómez-Lizarraga G, Martínez V. Molecules 26 4564 (2021)
  59. Glycopeptides and -Mimetics to Detect, Monitor and Inhibit Bacterial and Viral Infections: Recent Advances and Perspectives. Behren S, Westerlind U. Molecules 24 E1004 (2019)
  60. Mannoside recognition and degradation by bacteria. Ladevèze S, Laville E, Despres J, Mosoni P, Potocki-Véronèse G. Biol Rev Camb Philos Soc 92 1969-1990 (2017)
  61. Role of D-mannose in urinary tract infections - a narrative review. Ala-Jaakkola R, Laitila A, Ouwehand AC, Lehtoranta L. Nutr J 21 18 (2022)
  62. Sex effects in pyelonephritis. Albracht CD, Hreha TN, Hunstad DA. Pediatr Nephrol 36 507-515 (2021)
  63. Bacteria in Fluid Flow. Padron GC, Shuppara AM, Palalay JS, Sharma A, Sanfilippo JE. J Bacteriol 205 e0040022 (2023)
  64. Examination of Complementary Medicine for Treating Urinary Tract Infections Among Pregnant Women and Children. Hudson RE, Job KM, Sayre CL, Krepkova LV, Sherwin CM, Enioutina EY. Front Pharmacol 13 883216 (2022)
  65. The yin-yang driving urinary tract infection and how proteomics can enhance research, diagnostics, and treatment. Floyd KA, Meyer AE, Nelson G, Hadjifrangiskou M. Proteomics Clin Appl 9 990-1002 (2015)
  66. Neutralizing Antibodies Against Allosteric Proteins: Insights From a Bacterial Adhesin. Sokurenko EV, Tchesnokova V, Interlandi G, Klevit R, Thomas WE. J Mol Biol 434 167717 (2022)
  67. The Clinical Trial Outcomes of Cranberry, D-Mannose and NSAIDs in the Prevention or Management of Uncomplicated Urinary Tract Infections in Women: A Systematic Review. Konesan J, Liu L, Mansfield KJ. Pathogens 11 1471 (2022)
  68. [Recurrent urinary tract infections in women. Virulence of pathogens and host reaction]. Oelschlaeger T, Fünfstück R. Urologe A 45 412, 414-6, 418-20 (2006)
  69. Glycomimetics for the inhibition and modulation of lectins. Leusmann S, Ménová P, Shanin E, Titz A, Rademacher C. Chem Soc Rev 52 3663-3740 (2023)
  70. Nature of the Interaction of Alpha-D-Mannose and Escherichia coli Bacteria, and Implications for its Regulatory Classification. A Delphi Panel European Consensus Based on Chemistry and Legal Evidence. Scaglione F, Minghetti P, Ambrosio F, Ernst B, Ficarra V, Gobbi M, Naber K, Schellekens H. Ther Innov Regul Sci 57 1153-1166 (2023)
  71. Non-antibiotic Approaches to Preventing Pediatric UTIs: a Role for D-Mannose, Cranberry, and Probiotics? Ching CB. Curr Urol Rep 23 113-127 (2022)

Articles citing this publication (132)

  1. Maximising multivalency effects in protein-carbohydrate interactions. Pieters RJ. Org Biomol Chem 7 2013-2025 (2009)
  2. Structural basis for mechanical force regulation of the adhesin FimH via finger trap-like beta sheet twisting. Le Trong I, Aprikian P, Kidd BA, Forero-Shelton M, Tchesnokova V, Rajagopal P, Rodriguez V, Interlandi G, Klevit R, Vogel V, Stenkamp RE, Sokurenko EV, Thomas WE. Cell 141 645-655 (2010)
  3. FimH forms catch bonds that are enhanced by mechanical force due to allosteric regulation. Yakovenko O, Sharma S, Forero M, Tchesnokova V, Aprikian P, Kidd B, Mach A, Vogel V, Sokurenko E, Thomas WE. J Biol Chem 283 11596-11605 (2008)
  4. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. Kranjčec B, Papeš D, Altarac S. World J Urol 32 79-84 (2014)
  5. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. Han Z, Pinkner JS, Ford B, Obermann R, Nolan W, Wildman SA, Hobbs D, Ellenberger T, Cusumano CK, Hultgren SJ, Janetka JW. J Med Chem 53 4779-4792 (2010)
  6. Glycomimetics and glycodendrimers as high affinity microbial anti-adhesins. Imberty A, Chabre YM, Roy R. Chemistry 14 7490-7499 (2008)
  7. Catch-bond mechanism of the bacterial adhesin FimH. Sauer MM, Jakob RP, Eras J, Baday S, Eriş D, Navarra G, Bernèche S, Ernst B, Maier T, Glockshuber R. Nat Commun 7 10738 (2016)
  8. A central metabolic circuit controlled by QseC in pathogenic Escherichia coli. Hadjifrangiskou M, Kostakioti M, Chen SL, Henderson JP, Greene SE, Hultgren SJ. Mol Microbiol 80 1516-1529 (2011)
  9. Mannosylated G(0) dendrimers with nanomolar affinities to Escherichia coli FimH. Touaibia M, Wellens A, Shiao TC, Wang Q, Sirois S, Bouckaert J, Roy R. ChemMedChem 2 1190-1201 (2007)
  10. Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation. Schwartz DJ, Kalas V, Pinkner JS, Chen SL, Spaulding CN, Dodson KW, Hultgren SJ. Proc Natl Acad Sci U S A 110 15530-15537 (2013)
  11. Structural basis for Acinetobacter baumannii biofilm formation. Pakharukova N, Tuittila M, Paavilainen S, Malmi H, Parilova O, Teneberg S, Knight SD, Zavialov AV. Proc Natl Acad Sci U S A 115 5558-5563 (2018)
  12. The functional valency of dodecamannosylated fullerenes with Escherichia coli FimH--towards novel bacterial antiadhesives. Durka M, Buffet K, Iehl J, Holler M, Nierengarten JF, Taganna J, Bouckaert J, Vincent SP. Chem Commun (Camb) 47 1321-1323 (2011)
  13. Transposon mutagenesis identifies uropathogenic Escherichia coli biofilm factors. Hadjifrangiskou M, Gu AP, Pinkner JS, Kostakioti M, Zhang EW, Greene SE, Hultgren SJ. J Bacteriol 194 6195-6205 (2012)
  14. Evaluation of the carbohydrate recognition domain of the bacterial adhesin FimH: Design, synthesis and binding properties of mannoside ligands. Sperling O, Fuchs A, Lindhorst TK. Org Biomol Chem 4 3913-3922 (2006)
  15. Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. Han Z, Pinkner JS, Ford B, Chorell E, Crowley JM, Cusumano CK, Campbell S, Henderson JP, Hultgren SJ, Janetka JW. J Med Chem 55 3945-3959 (2012)
  16. Molecular variations in Klebsiella pneumoniae and Escherichia coli FimH affect function and pathogenesis in the urinary tract. Rosen DA, Pinkner JS, Walker JN, Elam JS, Jones JM, Hultgren SJ. Infect Immun 76 3346-3356 (2008)
  17. The bacterial fimbrial tip acts as a mechanical force sensor. Aprikian P, Interlandi G, Kidd BA, Le Trong I, Tchesnokova V, Yakovenko O, Whitfield MJ, Bullitt E, Stenkamp RE, Thomas WE, Sokurenko EV. PLoS Biol 9 e1000617 (2011)
  18. Structural basis of high-affinity glycan recognition by bacterial and fungal lectins. Imberty A, Mitchell EP, Wimmerová M. Curr Opin Struct Biol 15 525-534 (2005)
  19. A graphene-conjugated oligomer hybrid probe for light-up sensing of lectin and Escherichia coli. Wang L, Pu KY, Li J, Qi X, Li H, Zhang H, Fan C, Liu B. Adv Mater 23 4386-4391 (2011)
  20. Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections. Mydock-McGrane L, Cusumano Z, Han Z, Binkley J, Kostakioti M, Hannan T, Pinkner JS, Klein R, Kalas V, Crowley J, Rath NP, Hultgren SJ, Janetka JW. J Med Chem 59 9390-9408 (2016)
  21. Synthetic multimeric heptyl mannosides as potent antiadhesives of uropathogenic Escherichia coli. Gouin SG, Wellens A, Bouckaert J, Kovensky J. ChemMedChem 4 749-755 (2009)
  22. Elevated shear stress protects Escherichia coli cells adhering to surfaces via catch bonds from detachment by soluble inhibitors. Nilsson LM, Thomas WE, Sokurenko EV, Vogel V. Appl Environ Microbiol 72 3005-3010 (2006)
  23. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Schwardt O, Rabbani S, Hartmann M, Abgottspon D, Wittwer M, Kleeb S, Zalewski A, Smieško M, Cutting B, Ernst B. Bioorg Med Chem 19 6454-6473 (2011)
  24. Development of Heptylmannoside-Based Glycoconjugate Antiadhesive Compounds against Adherent-Invasive Escherichia coli Bacteria Associated with Crohn's Disease. Sivignon A, Yan X, Alvarez Dorta D, Bonnet R, Bouckaert J, Fleury E, Bernard J, Gouin SG, Darfeuille-Michaud A, Barnich N. mBio 6 e01298-15 (2015)
  25. FleA Expression in Aspergillus fumigatus Is Recognized by Fucosylated Structures on Mucins and Macrophages to Prevent Lung Infection. Kerr SC, Fischer GJ, Sinha M, McCabe O, Palmer JM, Choera T, Lim FY, Wimmerova M, Carrington SD, Yuan S, Lowell CA, Oscarson S, Keller NP, Fahy JV. PLoS Pathog 12 e1005555 (2016)
  26. Oligomannoside mimetics by glycosylation of 'octopus glycosides' and their investigation as inhibitors of type 1 fimbriae-mediated adhesion of Escherichia coli. Dubber M, Sperling O, Lindhorst TK. Org Biomol Chem 4 3901-3912 (2006)
  27. Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection. Kostakioti M, Hadjifrangiskou M, Cusumano CK, Hannan TJ, Janetka JW, Hultgren SJ. Infect Immun 80 2826-2834 (2012)
  28. Luminescent rhenium(I) polypyridine complexes appended with an α-D-glucose moiety as novel biomolecular and cellular probes. Louie MW, Liu HW, Lam MH, Lam YW, Lo KK. Chemistry 17 8304-8308 (2011)
  29. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI. Jarvis C, Han Z, Kalas V, Klein R, Pinkner JS, Ford B, Binkley J, Cusumano CK, Cusumano Z, Mydock-McGrane L, Hultgren SJ, Janetka JW. ChemMedChem 11 367-373 (2016)
  30. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Lenger SM, Bradley MS, Thomas DA, Bertolet MH, Lowder JL, Sutcliffe S. Am J Obstet Gynecol 223 265.e1-265.e13 (2020)
  31. Heptyl α-D-mannosides grafted on a β-cyclodextrin core to interfere with Escherichia coli adhesion: an in vivo multivalent effect. Bouckaert J, Li Z, Xavier C, Almant M, Caveliers V, Lahoutte T, Weeks SD, Kovensky J, Gouin SG. Chemistry 19 7847-7855 (2013)
  32. Lectin-Glycan Interaction Network-Based Identification of Host Receptors of Microbial Pathogenic Adhesins. Ielasi FS, Alioscha-Perez M, Donohue D, Claes S, Sahli H, Schols D, Willaert RG. mBio 7 e00584-16 (2016)
  33. The Antiadhesive Strategy in Crohn's Disease: Orally Active Mannosides to Decolonize Pathogenic Escherichia coli from the Gut. Alvarez Dorta D, Sivignon A, Chalopin T, Dumych TI, Roos G, Bilyy RO, Deniaud D, Krammer EM, de Ruyck J, Lensink MF, Bouckaert J, Barnich N, Gouin SG. Chembiochem 17 936-952 (2016)
  34. Clustering of Escherichia coli type-1 fimbrial adhesins by using multimeric heptyl α-D-mannoside probes with a carbohydrate core. Almant M, Moreau V, Kovensky J, Bouckaert J, Gouin SG. Chemistry 17 10029-10038 (2011)
  35. Highly conserved type 1 pili promote enterotoxigenic E. coli pathogen-host interactions. Sheikh A, Rashu R, Begum YA, Kuhlman FM, Ciorba MA, Hultgren SJ, Qadri F, Fleckenstein JM. PLoS Negl Trop Dis 11 e0005586 (2017)
  36. Inhibition and Reversal of Microbial Attachment by an Antibody with Parasteric Activity against the FimH Adhesin of Uropathogenic E. coli. Kisiela DI, Avagyan H, Friend D, Jalan A, Gupta S, Interlandi G, Liu Y, Tchesnokova V, Rodriguez VB, Sumida JP, Strong RK, Wu XR, Thomas WE, Sokurenko EV. PLoS Pathog 11 e1004857 (2015)
  37. Inhibition of bacterial adhesion to live human cells: activity and cytotoxicity of synthetic mannosides. Hartmann M, Papavlassopoulos H, Chandrasekaran V, Grabosch C, Beiroth F, Lindhorst TK, Röhl C. FEBS Lett 586 1459-1465 (2012)
  38. Squaric acid monoamide mannosides as ligands for the bacterial lectin FimH: covalent inhibition or not? Grabosch C, Hartmann M, Schmidt-Lassen J, Lindhorst TK. Chembiochem 12 1066-1074 (2011)
  39. Glycosylation changes as important factors for the susceptibility to urinary tract infection. Taganna J, de Boer AR, Wuhrer M, Bouckaert J. Biochem Soc Trans 39 349-354 (2011)
  40. Effects of a new combination of  plant extracts plus d-mannose for the management of uncomplicated recurrent urinary tract infections. Genovese C, Davinelli S, Mangano K, Tempera G, Nicolosi D, Corsello S, Vergalito F, Tartaglia E, Scapagnini G, Di Marco R. J Chemother 30 107-114 (2018)
  41. Recognition of the N-terminal lectin domain of FimH adhesin by the usher FimD is required for type 1 pilus biogenesis. Munera D, Hultgren S, Fernández LA. Mol Microbiol 64 333-346 (2007)
  42. Allosteric coupling in the bacterial adhesive protein FimH. Rodriguez VB, Kidd BA, Interlandi G, Tchesnokova V, Sokurenko EV, Thomas WE. J Biol Chem 288 24128-24139 (2013)
  43. FimH antagonists: structure-activity and structure-property relationships for biphenyl α-D-mannopyranosides. Pang L, Kleeb S, Lemme K, Rabbani S, Scharenberg M, Zalewski A, Schädler F, Schwardt O, Ernst B. ChemMedChem 7 1404-1422 (2012)
  44. A bivalent glycopeptide to target two putative carbohydrate binding sites on FimH. Lindhorst TK, Bruegge K, Fuchs A, Sperling O. Beilstein J Org Chem 6 801-809 (2010)
  45. Suppression of type 1 pilus assembly in uropathogenic Escherichia coli by chemical inhibition of subunit polymerization. Lo AW, Van de Water K, Gane PJ, Chan AW, Steadman D, Stevens K, Selwood DL, Waksman G, Remaut H. J Antimicrob Chemother 69 1017-1026 (2014)
  46. Biosensor for selective detection of E. coli in spinach using the strong affinity of derivatized mannose with fimbrial lectin. Yazgan I, Noah NM, Toure O, Zhang S, Sadik OA. Biosens Bioelectron 61 266-273 (2014)
  47. Inhibition profiles of mono- and polyvalent FimH antagonists against 10 different Escherichia coli strains. Chalopin T, Brissonnet Y, Sivignon A, Deniaud D, Cremet L, Barnich N, Bouckaert J, Gouin SG. Org Biomol Chem 13 11369-11375 (2015)
  48. Interaction of microbes with mucus and mucins: recent developments. Naughton J, Duggan G, Bourke B, Clyne M. Gut Microbes 5 48-52 (2014)
  49. Role for FimH in Extraintestinal Pathogenic Escherichia coli Invasion and Translocation through the Intestinal Epithelium. Poole NM, Green SI, Rajan A, Vela LE, Zeng XL, Estes MK, Maresso AW. Infect Immun 85 e00581-17 (2017)
  50. Synthesis and testing of the first azobenzene mannobioside as photoswitchable ligand for the bacterial lectin FimH. Chandrasekaran V, Kolbe K, Beiroth F, Lindhorst TK. Beilstein J Org Chem 9 223-233 (2013)
  51. The tyrosine gate of the bacterial lectin FimH: a conformational analysis by NMR spectroscopy and X-ray crystallography. Fiege B, Rabbani S, Preston RC, Jakob RP, Zihlmann P, Schwardt O, Jiang X, Maier T, Ernst B. Chembiochem 16 1235-1246 (2015)
  52. Tri- and hexavalent mannoside clusters as potential inhibitors of type 1 fimbriated bacteria using pentaerythritol and triazole linkages. Touaibia M, Shiao TC, Papadopoulos A, Vaucher J, Wang Q, Benhamioud K, Roy R. Chem Commun (Camb) 380-382 (2007)
  53. Chloroplasts assemble the major subunit FaeG of Escherichia coli F4 (K88) fimbriae to strand-swapped dimers. Van Molle I, Joensuu JJ, Buts L, Panjikar S, Kotiaho M, Bouckaert J, Wyns L, Niklander-Teeri V, De Greve H. J Mol Biol 368 791-799 (2007)
  54. Inactive conformation enhances binding function in physiological conditions. Yakovenko O, Tchesnokova V, Sokurenko EV, Thomas WE. Proc Natl Acad Sci U S A 112 9884-9889 (2015)
  55. Surprising Antibacterial Activity and Selectivity of Hydrophilic Polyphosphoniums Featuring Sugar and Hydroxy Substituents. Cuthbert TJ, Hisey B, Harrison TD, Trant JF, Gillies ER, Ragogna PJ. Angew Chem Int Ed Engl 57 12707-12710 (2018)
  56. The UbiI (VisC) Aerobic Ubiquinone Synthase Is Required for Expression of Type 1 Pili, Biofilm Formation, and Pathogenesis in Uropathogenic Escherichia coli. Floyd KA, Mitchell CA, Eberly AR, Eberly AR, Colling SJ, Zhang EW, DePas W, Chapman MR, Conover M, Rogers BR, Hultgren SJ, Hadjifrangiskou M. J Bacteriol 198 2662-2672 (2016)
  57. Development of an aggregation assay to screen FimH antagonists. Abgottspon D, Rölli G, Hosch L, Steinhuber A, Jiang X, Schwardt O, Cutting B, Smiesko M, Jenal U, Ernst B, Trampuz A. J Microbiol Methods 82 249-255 (2010)
  58. Effect of dietary beta1-4 mannobiose in the prevention of Salmonella enteritidis infection in broilers. Agunos A, Ibuki M, Yokomizo F, Mine Y. Br Poult Sci 48 331-341 (2007)
  59. Use of D-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. Altarac S, Papeš D. BJU Int 113 9-10 (2014)
  60. The price of flexibility - a case study on septanoses as pyranose mimetics. Sager CP, Fiege B, Zihlmann P, Vannam R, Rabbani S, Jakob RP, Preston RC, Zalewski A, Maier T, Peczuh MW, Ernst B. Chem Sci 9 646-654 (2018)
  61. Beyond induced-fit receptor-ligand interactions: structural changes that can significantly extend bond lifetimes. Nilsson LM, Thomas WE, Sokurenko EV, Vogel V. Structure 16 1047-1058 (2008)
  62. Bi- and trivalent glycopeptide mannopyranosides as inhibitors of type 1 fimbriae-mediated bacterial adhesion: variation of valency, aglycon and scaffolding. Schierholt A, Hartmann M, Lindhorst TK. Carbohydr Res 346 1519-1526 (2011)
  63. Fimbrial adhesins from extraintestinal Escherichia coli. Klemm P, Hancock V, Schembri MA. Environ Microbiol Rep 2 628-640 (2010)
  64. Open label feasibility study evaluating D-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis. Phé V, Pakzad M, Haslam C, Gonzales G, Curtis C, Porter B, Chataway J, Panicker JN. Neurourol Urodyn 36 1770-1775 (2017)
  65. Validation of Reactivity Descriptors to Assess the Aromatic Stacking within the Tyrosine Gate of FimH. Roos G, Wellens A, Touaibia M, Yamakawa N, Geerlings P, Roy R, Wyns L, Bouckaert J. ACS Med Chem Lett 4 1085-1090 (2013)
  66. Mechanistic insights into the host-microbe interaction and pathogen exclusion mediated by the Mucus-binding protein of Lactobacillus plantarum. Singh KS, Kumar S, Mohanty AK, Grover S, Kaushik JK. Sci Rep 8 14198 (2018)
  67. MrpH, a new class of metal-binding adhesin, requires zinc to mediate biofilm formation. Jiang W, Ubhayasekera W, Breed MC, Norsworthy AN, Serr N, Mobley HLT, Pearson MM, Knight SD. PLoS Pathog 16 e1008707 (2020)
  68. Broad-spectrum neutralization of avian influenza viruses by sialylated human milk oligosaccharides: in vivo assessment of 3'-sialyllactose against H9N2 in chickens. Pandey RP, Kim DH, Woo J, Song J, Jang SH, Kim JB, Cheong KM, Oh JS, Sohng JK. Sci Rep 8 2563 (2018)
  69. Structural and functional insight into the carbohydrate receptor binding of F4 fimbriae-producing enterotoxigenic Escherichia coli. Moonens K, Van den Broeck I, De Kerpel M, Deboeck F, Raymaekers H, Remaut H, De Greve H. J Biol Chem 290 8409-8419 (2015)
  70. The Conformational Variability of FimH: Which Conformation Represents the Therapeutic Target? Eris D, Preston RC, Scharenberg M, Hulliger F, Abgottspon D, Pang L, Jiang X, Schwardt O, Ernst B. Chembiochem 17 1012-1020 (2016)
  71. A flow cytometry-based assay for screening FimH antagonists. Scharenberg M, Abgottspon D, Cicek E, Jiang X, Schwardt O, Rabbani S, Ernst B. Assay Drug Dev Technol 9 455-464 (2011)
  72. Kinetic properties of carbohydrate-lectin interactions: FimH antagonists. Scharenberg M, Jiang X, Pang L, Navarra G, Rabbani S, Binder F, Schwardt O, Ernst B. ChemMedChem 9 78-83 (2014)
  73. Specific residues in the N-terminal domain of FimH stimulate type 1 fimbriae assembly in Escherichia coli following the initial binding of the adhesin to FimD usher. Munera D, Palomino C, Fernández LA. Mol Microbiol 69 911-925 (2008)
  74. Improvement of Aglycone π-Stacking Yields Nanomolar to Sub-nanomolar FimH Antagonists. Schönemann W, Cramer J, Mühlethaler T, Fiege B, Silbermann M, Rabbani S, Dätwyler P, Zihlmann P, Jakob RP, Sager CP, Smieško M, Schwardt O, Maier T, Ernst B. ChemMedChem 14 749-757 (2019)
  75. Nanoscale surface modification favors benign biofilm formation and impedes adherence by pathogens. Trautner BW, Lopez AI, Kumar A, Siddiq DM, Liao KS, Li Y, Tweardy DJ, Cai C. Nanomedicine 8 261-270 (2012)
  76. Niche-specific contribution to streptococcal virulence of a MalR-regulated carbohydrate binding protein. Shelburne SA, Sahasrobhajane P, Suber B, Keith DB, Davenport MT, Horstmann N, Kumaraswami M, Olsen RJ, Brennan RG, Musser JM. Mol Microbiol 81 500-514 (2011)
  77. Subinhibitory Concentrations of Allicin Decrease Uropathogenic Escherichia coli (UPEC) Biofilm Formation, Adhesion Ability, and Swimming Motility. Yang X, Sha K, Xu G, Tian H, Wang X, Chen S, Wang Y, Li J, Chen J, Huang N. Int J Mol Sci 17 E979 (2016)
  78. Adhesion of Escherichia coli under flow conditions reveals potential novel effects of FimH mutations. Feenstra T, Thøgersen MS, Wieser E, Peschel A, Ball MJ, Brandes R, Satchell SC, Stockner T, Aarestrup FM, Rees AJ, Kain R. Eur J Clin Microbiol Infect Dis 36 467-478 (2017)
  79. Biotinylated bi- and tetra-antennary glycoconjugates for Escherichia coli detection. Hatch DM, Weiss AA, Kale RR, Iyer SS. Chembiochem 9 2433-2442 (2008)
  80. Conformational switch of the bacterial adhesin FimH in the absence of the regulatory domain: Engineering a minimalistic allosteric system. Rabbani S, Fiege B, Eris D, Silbermann M, Jakob RP, Navarra G, Maier T, Ernst B. J Biol Chem 293 1835-1849 (2018)
  81. Crystal structure of the MrkD1P receptor binding domain of Klebsiella pneumoniae and identification of the human collagen V binding interface. Rêgo AT, Johnson JG, Gelbel S, Enguita FJ, Clegg S, Waksman G. Mol Microbiol 86 882-893 (2012)
  82. Glycointeractome of Neisseria gonorrhoeae: Identification of Host Glycans Targeted by the Gonococcus To Facilitate Adherence to Cervical and Urethral Epithelial Cells. Semchenko EA, Everest-Dass AV, Jen FE, Mubaiwa TD, Day CJ, Seib KL. mBio 10 e01339-19 (2019)
  83. Candidate targets for new antivirulence drugs: selected cases of bacterial adhesion and biofilm formation. Klemm P, Hancock V, Kvist M, Schembri MA. Future Microbiol 2 643-653 (2007)
  84. Conformational inactivation induces immunogenicity of the receptor-binding pocket of a bacterial adhesin. Kisiela DI, Rodriguez VB, Tchesnokova V, Avagyan H, Aprikian P, Liu Y, Wu XR, Thomas WE, Sokurenko EV. Proc Natl Acad Sci U S A 110 19089-19094 (2013)
  85. Mechanism of allosteric propagation across a β-sheet structure investigated by molecular dynamics simulations. Interlandi G, Thomas WE. Proteins 84 990-1008 (2016)
  86. KinITC-One Method Supports both Thermodynamic and Kinetic SARs as Exemplified on FimH Antagonists. Zihlmann P, Silbermann M, Sharpe T, Jiang X, Mühlethaler T, Jakob RP, Rabbani S, Sager CP, Frei P, Frei P, Pang L, Maier T, Ernst B. Chemistry 24 13049-13057 (2018)
  87. Spontaneous detachment of Streptococcus mutans biofilm by synergistic effect between zwitterion and sugar alcohol. Lim JH, Song SH, Park HS, Lee JR, Lee SM. Sci Rep 7 8107 (2017)
  88. Virulence factors of uropathogens and their role in host pathogen interactions. Govindarajan DK, Kandaswamy K. Cell Surf 8 100075 (2022)
  89. A 'dual click' strategy for the fabrication of bioselective, glycosylated self-assembled monolayers as glycocalyx models. Grabosch C, Kind M, Gies Y, Schweighöfer F, Terfort A, Lindhorst TK. Org Biomol Chem 11 4006-4015 (2013)
  90. Glycopeptide dendrimers: tuning carbohydrate-lectin interactions with amino acids. Euzen R, Reymond JL. Mol Biosyst 7 411-421 (2011)
  91. Molecular dynamics simulations of lectin domain of FimH and immunoinformatics for the design of potential vaccine candidates. Singaravelu M, Selvan A, Anishetty S. Comput Biol Chem 52 18-24 (2014)
  92. 2D transition metal dichalcogenides with glucan multivalency for antibody-free pathogen recognition. Kang TW, Han J, Lee S, Hwang IJ, Jeon SJ, Ju JM, Kim MJ, Yang JK, Jun B, Lee CH, Lee SU, Kim JH. Nat Commun 9 2549 (2018)
  93. Discovery of Bacterial Fimbria-Glycan Interactions Using Whole-Cell Recombinant Escherichia coli Expression. Day CJ, Lo AW, Hartley-Tassell LE, Argente MP, Poole J, King NP, Tiralongo J, Jennings MP, Schembri MA. mBio 12 e03664-20 (2021)
  94. En route to photoaffinity labeling of the bacterial lectin FimH. Lindhorst TK, Märten M, Fuchs A, Knight SD. Beilstein J Org Chem 6 810-822 (2010)
  95. Role of Flagellin-Homologous Proteins in Biofilm Formation by Pathogenic Vibrio Species. Jung YC, Lee MA, Lee KH. mBio 10 e01793-19 (2019)
  96. Surface Plasmon Resonance (SPR) for the Evaluation of Shear-Force-Dependent Bacterial Adhesion. Zagorodko O, Bouckaert J, Dumych T, Bilyy R, Larroulet I, Yanguas Serrano A, Alvarez Dorta D, Gouin SG, Dima SO, Oancea F, Boukherroub R, Szunerits S. Biosensors (Basel) 5 276-287 (2015)
  97. Synthetic glycopeptides and glycoproteins with applications in biological research. Westerlind U. Beilstein J Org Chem 8 804-818 (2012)
  98. What does it take to stick around? Molecular insights into biofilm formation by uropathogenic Escherichia coli. Hadjifrangiskou M, Hultgren SJ. Virulence 3 231-233 (2012)
  99. A Novel Integrated Way for Deciphering the Glycan Code for the FimH Lectin. Dumych T, Bridot C, Gouin SG, Lensink MF, Paryzhak S, Szunerits S, Blossey R, Bilyy R, Bouckaert J, Krammer EM. Molecules 23 E2794 (2018)
  100. Comparative Study of Aryl O-, C-, and S-Mannopyranosides as Potential Adhesion Inhibitors toward Uropathogenic E. coli FimH. Mousavifar L, Vergoten G, Charron G, Roy R. Molecules 24 E3566 (2019)
  101. Differentiation of Crohn's Disease-Associated Isolates from Other Pathogenic Escherichia coli by Fimbrial Adhesion under Shear Force. Szunerits S, Zagorodko O, Cogez V, Dumych T, Chalopin T, Alvarez Dorta D, Sivignon A, Barnich N, Harduin-Lepers A, Larroulet I, Yanguas Serrano A, Siriwardena A, Pesquera A, Zurutuza A, Gouin SG, Boukherroub R, Bouckaert J. Biology (Basel) 5 E14 (2016)
  102. Ordered and ushered; the assembly and translocation of the adhesive type I and p pili. Lillington J, Waksman G. Biology (Basel) 2 841-860 (2013)
  103. Toggle switch residues control allosteric transitions in bacterial adhesins by participating in a concerted repacking of the protein core. Kisiela DI, Magala P, Interlandi G, Carlucci LA, Ramos A, Tchesnokova V, Basanta B, Yarov-Yarovoy V, Avagyan H, Hovhannisyan A, Thomas WE, Stenkamp RE, Klevit RE, Sokurenko EV. PLoS Pathog 17 e1009440 (2021)
  104. D-MannosE to prevent Recurrent urinary tract InfecTions (MERIT): protocol for a randomised controlled trial. Franssen M, Cook J, Robinson J, Williams N, Glogowska M, Yang Y, Allen J, Butler CC, Thomas N, Hay A, Moore M, Hayward G. BMJ Open 11 e037128 (2021)
  105. Heptylmannose-functionalized cellulose for the binding and specific detection of pathogenic E. coli. Cauwel M, Sivignon A, Bridot C, Nongbe MC, Deniaud D, Roubinet B, Landemarre L, Felpin FX, Bouckaert J, Barnich N, Gouin SG. Chem Commun (Camb) 55 10158-10161 (2019)
  106. Inactivated Salmonella expressing the receptor-binding domain of bacterial adhesins elicit antibodies inhibiting hemagglutination. Van Gerven N, De Greve H, Hernalsteens JP. Vet Microbiol 131 369-375 (2008)
  107. Mannosylated N-aryl substituted 3-hydroxypyridine-4-ones: synthesis, hemagglutination inhibitory properties, and molecular modeling. Car Z, Hrenar T, Petrović Peroković V, Ribić R, Seničar M, Tomić S. Chem Biol Drug Des 84 393-401 (2014)
  108. RMSD analysis of structures of the bacterial protein FimH identifies five conformations of its lectin domain. Magala P, Klevit RE, Thomas WE, Sokurenko EV, Stenkamp RE. Proteins 88 593-603 (2020)
  109. Supramolecular Recognition of Escherichia coli Bacteria by Fluorescent Oligo(Phenyleneethynylene)s with Mannopyranoside Termini Groups. Arias E, Méndez MT, Arias E, Moggio I, Ledezma A, Romero J, Margheri G, Giorgetti E. Sensors (Basel) 17 E1025 (2017)
  110. Are D-manno-configured Amadori products ligands of the bacterial lectin FimH? Gloe TE, Stamer I, Hojnik C, Wrodnigg TM, Lindhorst TK. Beilstein J Org Chem 11 1096-1104 (2015)
  111. Structures of two fimbrial adhesins, AtfE and UcaD, from the uropathogen Proteus mirabilis. Jiang W, Ubhayasekera W, Pearson MM, Knight SD. Acta Crystallogr D Struct Biol 74 1053-1062 (2018)
  112. Synthesis of glycopolymers with specificity for bacterial strains via bacteria-guided polymerization. Luo Y, Gu Y, Feng R, Brash J, Eissa AM, Haddleton DM, Chen G, Chen H. Chem Sci 10 5251-5257 (2019)
  113. Synthesis of oligomeric mannosides and their structure-binding relationship with concanavalin A. Li CW, Hon KW, Ghosh B, Li PH, Lin HY, Chan PH, Lin CH, Chen YC, Mong KK. Chem Asian J 9 1786-1796 (2014)
  114. Diazirine-functionalized mannosides for photoaffinity labeling: trouble with FimH. Beiroth F, Koudelka T, Overath T, Knight SD, Tholey A, Lindhorst TK. Beilstein J Org Chem 14 1890-1900 (2018)
  115. Enhancing the enthalpic contribution of hydrogen bonds by solvent shielding. Cramer J, Jiang X, Schönemann W, Silbermann M, Zihlmann P, Siegrist S, Fiege B, Jakob RP, Rabbani S, Maier T, Ernst B. RSC Chem Biol 1 281-287 (2020)
  116. Bifunctional mannoside-glucosinolate glycoconjugates as enzymatically triggered isothiocyanates and FimH ligands. Cutolo G, Reise F, Schuler M, Nehmé R, Despras G, Brekalo J, Morin P, Renard PY, Lindhorst TK, Tatibouët A. Org Biomol Chem 16 4900-4913 (2018)
  117. D-Mannoside FimH Inhibitors as Non-Antibiotic Alternatives for Uropathogenic Escherichia coli. Montes-Robledo A, Baldiris-Avila R, Galindo JF. Antibiotics (Basel) 10 1072 (2021)
  118. Effect of Aminophenyl and Aminothiahexyl α-D-Glycosides of the Manno-, Gluco-, and Galacto-Series on Type 1 Fimbriae-Mediated Adhesion of Escherichia coli. Fessele C, Lindhorst TK. Biology (Basel) 2 1135-1149 (2013)
  119. Enzymatic assay of D-mannose from urine. Mehta I, Zimmern P, Reitzer L. Bioanalysis 10 1947-1954 (2018)
  120. Shared unfolding pathways of unrelated immunoglobulin-like β-sandwich proteins. Toofanny RD, Calhoun S, Jonsson AL, Daggett V. Protein Eng Des Sel 32 331-345 (2019)
  121. Surfaces Presenting α-Phenyl Mannoside Derivatives Enable Formation of Stable, High Coverage, Non-pathogenic Escherichia coli Biofilms against Pathogen Colonization. Zhu Z, Wang J, Lopez AI, Yu F, Huang Y, Kumar A, Li S, Zhang L, Cai C. Biomater Sci 3 781-880 (2015)
  122. Visualization of melanoma tumor with lectin-conjugated rare-earth doped fluoride nanocrystals. Dumych T, Lutsyk M, Banski M, Yashchenko A, Sojka B, Horbay R, Lutsyk A, Stoika R, Misiewicz J, Podhorodecki A, Bilyy R. Croat Med J 55 186-194 (2014)
  123. Architecture of the biofilm-associated archaic Chaperone-Usher pilus CupE from Pseudomonas aeruginosa. Böhning J, Dobbelstein AW, Sulkowski N, Eilers K, von Kügelgen A, Tarafder AK, Peak-Chew SY, Skehel M, Alva V, Filloux A, Bharat TAM. PLoS Pathog 19 e1011177 (2023)
  124. Assembly and inhibitory activity of monovalent mannosides terminated with aromatic methyl esters: The effect of naphthyl groups. Al-Mughaid H, Al-Zoubi RM, Khazaaleh M, Grindley TB. Carbohydr Res 446-447 76-84 (2017)
  125. Bacterial Lectin FimH and Its Aggregation Hot-Spots: An Alternative Strategy against Uropathogenic Escherichia coli. Nasi GI, Georgakopoulou KI, Theodoropoulou MK, Papandreou NC, Chrysina ED, Tsiolaki PL, Iconomidou VA. Pharmaceutics 15 1018 (2023)
  126. Binding site plasticity regulation of the FimH catch-bond mechanism. Languin-Cattoën O, Sterpone F, Stirnemann G. Biophys J 122 2744-2756 (2023)
  127. FimH as a scaffold for regulated molecular recognition. Ludwig SG, Kiyohara CL, Carlucci LA, Kisiela D, Sokurenko EV, Thomas WE. J Biol Eng 15 3 (2021)
  128. Insights from the molecular docking analysis of SGLT2 and FIMH to combat uropathogenicity. Abdulaal WH, Bakhrebah MA, Nassar MS, Almazni IA, Almutairi WA, Natto ZS, Khattab AK. Bioinformation 18 1044-1049 (2022)
  129. Microelectrode array biosensor for studying carbohydrate-mediated interactions. Chamberlain JW, Maurer K, Cooper J, Lyon WJ, Danley DL, Ratner DM. Biosens Bioelectron 34 253-260 (2012)
  130. Pseudoenantiomeric glycoclusters: synthesis and testing of heterobivalency in carbohydrate-protein interactions. Brekalo J, Despras G, Lindhorst TK. Org Biomol Chem 17 5929-5942 (2019)
  131. Re: Comprehensive Mutagenesis of the FimS Promoter Regulatory Switch Reveals Novel Regulation of Type 1 Pili in Uropathogenic Escherichia coli. Atala A. J Urol 197 1463-1464 (2017)
  132. Sugar-Lectin Interactions for Direct and Selective Detection of Escherichia coli Bacteria Using QCM Biosensor. Eshun GB, Crapo HA, Yazgan I, Cronmiller L, Sadik OA. Biosensors (Basel) 13 337 (2023)


Quick links